Alexis Cortot

9PUBLICATIONS
118CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 08, 2026
Targeting Both Oncogenic Signaling and Dependence Receptor Function is Required to Fully Suppress MET Exon 14 Skipping-Driven tumorigenesis.

|Jun 09, 2026
Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

|Jul 08, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.

Fabrice Barlesi, Pascale Tomasini, Maryam Karimi

|Jan 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.

Julien Mazieres, Claire Lafitte, Charles Ricordel

|Nov 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Xiuning Le, Hiroshi Sakai, Enriqueta Felip

Pageof 2

Frequent Collaborators

4 joint publications

Julien Mazieres

4 joint publications

Denis Moro-Sibilot

3 joint publications

Eric Wasielewski

2 joint publications

Anne Madroszyk